Jyong Biotech Ltd. Ordinary Shares
Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder … Read more
Jyong Biotech Ltd. Ordinary Shares (MENS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: 0.025x
Based on the latest financial reports, Jyong Biotech Ltd. Ordinary Shares (MENS) has a cash flow conversion efficiency ratio of 0.025x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-913.00K) by net assets ($-36.52 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Jyong Biotech Ltd. Ordinary Shares - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Jyong Biotech Ltd. Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Jyong Biotech Ltd. Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jyong Biotech Ltd. Ordinary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MKH Bhd
KLSE:6114
|
0.032x |
|
Imas Makina Sanayi AS
IS:IMASM
|
0.046x |
|
Sanstar Ltd
NSE:SANSTAR
|
N/A |
|
Prevas AB Series B
LSE:0H2J
|
0.117x |
|
MedPeerInc
PINK:MDPEF
|
N/A |
|
Melhus Sparebank
OL:MELG
|
0.110x |
|
Soken Chemical & Engineering Co. Ltd
MU:SOQ
|
N/A |
|
Rorze Systems Corporation
KQ:071280
|
-0.028x |
Annual Cash Flow Conversion Efficiency for Jyong Biotech Ltd. Ordinary Shares (2020–2024)
The table below shows the annual cash flow conversion efficiency of Jyong Biotech Ltd. Ordinary Shares from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-36.52 Million | $-3.62 Million | 0.099x | +30.00% |
| 2023-12-31 | $-34.07 Million | $-2.60 Million | 0.076x | -23.87% |
| 2022-12-31 | $-29.63 Million | $-2.97 Million | 0.100x | +17.88% |
| 2021-12-31 | $-23.32 Million | $-1.98 Million | 0.085x | +50.27% |
| 2020-12-31 | $-19.20 Million | $-1.09 Million | 0.057x | -- |